Patents Examined by Y. Christina Chan
-
Patent number: 5320942Abstract: The present invention discloses a novel cell surface marker and antigenic portions thereof; antibodies reactive with said marker; polynucleotides encoding said marker and antigenic portions thereof; methods of diagnosis and treatment using said polynucleotides and antibodies.Type: GrantFiled: October 1, 1990Date of Patent: June 14, 1994Inventors: Vito Quaranta, Shama Kajiji
-
Patent number: 5306708Abstract: A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H SEQ ID NO:1 or OH SEQ ID NO:2 and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.Type: GrantFiled: December 19, 1990Date of Patent: April 26, 1994Assignee: Merck & Co., Inc.Inventors: Robert E. Schwartz, David F. Sesin, Prakash S. Masurekar, Jerrold M. Liesch, Thomas C. Hallada, Otto D. Hensens
-
Patent number: 5298420Abstract: Membrane anchoring peptides are attached to the C terminal end of the heavy chain of the various immunoglobulin isotypes (IgM, IgD, IgA, IgE, or IgG). The membrane anchoring peptides span the cell membrane lipid bilayer of B cells thereby affixing the associated immunoglobulin to the cell membrane surface. The extracellular segments of these peptides are unique for different isotypes. Epitopes unique to the B cells which produce each isotype are formed, in whole or in part, by these extracellular segments. These membrane-bound immunoglobulin isotype-specific ("migis") extracellular epitopes are not present on the secreted, soluble form of the immunoglobulins, which are not bound to the cell surface by the membrane anchoring peptides. The antibodies of the invention (and other related products) specifically bind to the extracellular migis epitopes of human .mu. chain, human .delta. chain, or human .gamma. chain.Type: GrantFiled: June 19, 1992Date of Patent: March 29, 1994Assignee: Tanox Biosystems, Inc.Inventor: Tse W. Chang
-
Patent number: 5292668Abstract: A homogenous sample of identical bispecific antibody determinants, each determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being specific for a different antigenic determinant and including at least the F(ab') portion of a monoclonal IgG antibody. The bispecific antibody determinants are useful, e.g., in the formation of multilamellar assemblies and in enzymatic assays.Type: GrantFiled: December 5, 1990Date of Patent: March 8, 1994Assignee: Boston Biomedical Research Institute, Inc.Inventor: Henry P. Paulus
-
Patent number: 5286654Abstract: An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.Type: GrantFiled: February 3, 1993Date of Patent: February 15, 1994Assignee: Genentech, Inc.Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
-
Patent number: 5284826Abstract: Hydroxy-substituted [(D)Ser].sup.8 -Ciclosporin derivatives, particularly [O-(2-hydroxyethyl)(D)Ser].sup.8 -Ciclosporin, have advantageous pharmacological properties and are useful as immunosuppressants, for example in the treatment of transplant rejection and autoimmune diseases.Type: GrantFiled: August 27, 1992Date of Patent: February 8, 1994Assignee: Sandoz Ltd.Inventor: Marcel K. Eberle
-
Patent number: 5278143Abstract: Unique methods for treating interleukin-mediated edemas in living subjects are provided comprising administering an effective amount of a composition selected from the group consisting of phallotoxins, phallotoxin analogues, antamanide, or an antamanide analogue to the subject. The methods offer prophylactic and therapeutic modes of treatment for both localized and systemic interleukin-mediated edemas. The compositions of choice may be applied topically or given parenterally; and may be employed with other diverse agents for treatment of both inflammatory and non-inflammatory edemas.Type: GrantFiled: December 16, 1991Date of Patent: January 11, 1994Assignee: Trustees of Boston UniversityInventors: David Shepro, J. Steven Alexander
-
Patent number: 5275935Abstract: An amebic glycoconjugate is disclosed that is recognized by an Entamoeba histolytica specific monoclonal antibody The glycoconjugate is isolated from the lysates of E. histolytica trophozoites, it is phosphorylated, lipid-containing, glycosylated, migrates as a polydisperse band on SDS-PAGE between about 65-200 kDa and is specifically recognized by monoclonal antibody CC 8.6, ATCC HB 11104.Type: GrantFiled: September 10, 1992Date of Patent: January 4, 1994Assignee: Washington UniversityInventors: Samuel L. Stanley, Jr., Ellen Li
-
Patent number: 5276016Abstract: Short peptide of the formula:R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.b (I)where R.sup.a represents an amino terminal residue Ala- or D-Ala and R.sup.b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II):R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II)whereR.sup.1 is an amino terminal residue Thr-, Ser-, Asn-,Leu-,Ile-,Arg- or Glu-R.sup.2 is Thr, Ser or AspR.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or TrpR.sup.4 is Tyr andR.sup.5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals,or a physiologically acceptable salt thereof.Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors.Type: GrantFiled: August 16, 1990Date of Patent: January 4, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Candace B. Pert, Michael R. Ruff, William L. Farrar
-
Patent number: 5273901Abstract: This invention relates to novel recombinant antigenic proteins of avian coccidiosis, and fragments thereof containing antigenic determinants, and to the genes that encode the antigenic peptides. This invention also relates to vaccines made using the novel antigenic proteins of avian coccidiosis and to methods of immunizing chickens against avian coccidia.Type: GrantFiled: September 12, 1990Date of Patent: December 28, 1993Assignees: Enzon Corp., U.S. Dept. of AgricultureInventors: James W. Jacobson, Robert L. Strausberg, Susan D. Wilson, Sharon H. Pope, Susan L. Strausberg, Michael D. Ruff, Patricia C. Augustine, Harry D. Danforth
-
Patent number: 5271927Abstract: The conjugation of antibodies to a macrocyclic conjugate compound wherein the conjugate compound has the structure (I), wherein R.sup.1 is --(CH.sub.2).sub.p --R.sup.6 --CH.sub.2).sub.q -- where p and q are the same or different and are 0, 1 or 2, and --R.sup.6 -- is --((CH.sub.2).sub.n --, where n is 0 or 1, --NH--, --O--, --S-- or (II), R.sup.1 optionally being alkyl substituted, provided that neither p nor q is 0 unless R.sup.6 is --CH.sub.2 --; R.sup.2 are --CH.sub.2 CH.sub.2 -- or --CH.sub.2 CH.sub.2 CH.sub.2 --, optionally alkyl, alkoxyalkyl or hydroxyalkyl substituted; R.sup.3 are the same or different and are --H, alkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl, carboxyalkyl ester, phosphate, sulphonate or phosphonate; R.sup.4 is one of the compounds of formula (III) optionally alkyl substituted, wherein R.sup.7 is --H, alkyl, hydroxyalkyl, or alkoxyalkyl provided that when R.sup.4 is (III d), R.sup.3 is not carboxyalkyl, R.sup.5 is a linker, and Ab is an antibody.Type: GrantFiled: March 18, 1993Date of Patent: December 21, 1993Assignee: Celltech LimitedInventors: David Parker, Thomas A. Millican
-
Patent number: 5270202Abstract: This application discloses a novel anti-idiotypic antibody, IMelpg2 and equivalents thereof, as well as, antibody fragments, peptides or antisera capable of reacting with at least one of the idiotopes of: (a) murine monoclonal antibody MEM136 and derivatives thereof; (b) a monoclonal antibody secreted by hybridomas from any species having the same immunological specificity as antibody MEM136; or (c) any polyclonal antibodies from any species having the same immunological specificity as antibody MEM136, wherein (a), (b), or (c) is capable of reacting with a specific determinant (epitope) of a MPG antigen are described, together with their preparation and use in the diagnosis, monitoring and treatment of tumors such as melanoma or other diseased cells that express the MPG epitope recognized by antibody MEM136.Type: GrantFiled: March 12, 1991Date of Patent: December 14, 1993Inventor: Syamal Raychaudhuri
-
Patent number: 5260210Abstract: An in vitro model of a blood-brain barrier comprising a porous solid support upon which is disposed an essentially confluent monolayer of brain microvascular endothelial cells in contact with agents that elevate effective cyclic AMP concentrations in endothelial cells, with or without astrocyte-derived or endothelial cell-derived conditioned medium or the equivalent so that high electrical resistance tight junctions are formed between endothelial cells, and endothelial cells exhibit peripheral phalloidin staining and E-cadherin. Also disclosed is the use of agents that reduce effective cyclic AMP concentrations or interfere with the functioning of cyclic AMP or increase effective cyclic GMP concentrations to open up blood-brain barriers in vitro and in vivo, so that drugs normally excluded by such barriers may substantially penetrate such barriers. Also disclosed are uses of the model to screen for reagents with clinical utility in disorders involving brain endothelial cells.Type: GrantFiled: September 4, 1990Date of Patent: November 9, 1993Inventors: Lee L. Rubin, Seth Porter, Heidi C. Horner, Theodore A. Yednick
-
Patent number: 5260057Abstract: This invention describes a product obtained from the isolation and concentration of specific immunoglobulins (antibodies) derived from the mammary secretions of cows immunized with Helicobacter pylori. The product is useful in preparing formulations for the treatment and/or prevention of gastric diseases.Type: GrantFiled: December 31, 1992Date of Patent: November 9, 1993Assignee: Abbott LaboratoriesInventors: Christopher T. Cordle, Joseph P. Schaller
-
Patent number: 5258495Abstract: A process for the manufacture of vancomycin.HCl which does not require preparation of a phosphate intermediate. The process consists of loading a vancomycin onto a suitable adsorbent and eluting the vancomycin solution therefrom with an ammonium solvent followed by loading the vancomycin solution onto a suitable adsorbent and eluting the purified, vancomycin solution therefrom with a solvent of alcohol and acid. The purified vancomycin is then crystallized from the solution by combining the solution with a sufficient amount of NH.sub.4 Cl to provide a pH of about 2.0 to about 3.5. The crystals are then dissolved in solution. The dissolved solution is combined with acid and the vancomycin recrystallizes from the solution.Type: GrantFiled: April 27, 1992Date of Patent: November 2, 1993Assignee: Abbott LaboratoriesInventor: Alexander H. T. Chu
-
Patent number: 5258493Abstract: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.Type: GrantFiled: March 16, 1992Date of Patent: November 2, 1993Assignee: Bio-Mega/Boehringer Ingelheim Research Inc.Inventors: Julian Adams, John DiMaio, Raymond Plante
-
Patent number: 5256559Abstract: This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this invention are advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or a biological sample. These methods, compositions and combinations are particularly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods, compositions and combinations for treating extracorporeal blood and for increasing platelet storage life.Type: GrantFiled: March 27, 1991Date of Patent: October 26, 1993Assignees: Biogen, Inc., Trustees of Boston UniversityInventors: John M. Maraganore, Joseph A. Jakubowski
-
Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
Patent number: 5254671Abstract: Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane are disclosed. For IgE, the epitopes are present on IgE-bearing B cells but not basophils or the secreted, soluble form of IgE. The epitope can be exploited for therapy and diagnosis. For example, antibodies or immunotoxins specific for the epitopes associated with the anchor domain of IgE can be used to selectively destroy or downregulate IgE-bearing lymphocytes, thus blocking IgE-mediated allergic reactions. Three different isoforms of the C-terminal segment of the human .epsilon. chain resulting from alternative mRNA splicings in the membrane exon region are disclosed, one of which is secreted and not membrane-bound.Type: GrantFiled: October 29, 1992Date of Patent: October 19, 1993Assignee: Tanox Biosystems, Inc.Inventor: Tse W. Chang -
Patent number: 5248667Abstract: Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in patients who lack antibodies against HIV.Type: GrantFiled: July 18, 1991Date of Patent: September 28, 1993Assignee: The United States of America as represented by the Secretary of the Department of Health & Human ServicesInventors: Peter Bridge, Frederick K. Goodwin
-
Patent number: 5239057Abstract: The present invention is directed to a fluorescence polarization immunoassay for cyclosporin A and metabolites thereof. The present invention also relates to novel cyclosporin A derivative compounds useful in fluorescence polarization techniques. Included among the novel compounds are cyclosporin A derivatives where the amino acid in the first position is altered. The cyclosporin A derivatives are useful in forming immunogens for raising antibodies specific to cyclosporin A and metabolites thereof.Type: GrantFiled: October 15, 1991Date of Patent: August 24, 1993Assignee: Abbott LaboratoriesInventors: Nai-Yi Wang, Philip P. Wang, Marjorie A. Morrison